Current Alzheimer's Medications vs. Cuba's Neuroprotective Approach

The Global Alzheimer's Treatment Landscape

Alzheimer's disease affects over 55 million people worldwide, yet treatment options remain limited. Conventional pharmacological approaches focus primarily on managing symptoms rather than addressing the underlying disease process. In recent years, new disease-modifying therapies have emerged, but they come with significant limitations, costs, and safety concerns.

Cuba's approach — centered on NeuroEPO/NeuralCIM® neuroprotective therapy combined with intensive cognitive rehabilitation — offers a different paradigm. Rather than targeting a single molecular pathway, Cuba's multidisciplinary program addresses multiple aspects of neurodegeneration simultaneously: neuroprotection, cognitive stimulation, functional rehabilitation, and caregiver support.

Understanding how these approaches compare helps patients and families make informed decisions about treatment options.

Conventional Alzheimer's Medications

The standard pharmacological treatments for Alzheimer's fall into several categories:

1. Cholinesterase Inhibitors (donepezil, rivastigmine, galantamine): • Mechanism: Prevent the breakdown of acetylcholine, a neurotransmitter important for memory and thinking. • Indication: Mild to moderate Alzheimer's (donepezil also approved for severe). • Benefits: May temporarily improve cognition and behavior in some patients. Modest effect size. • Limitations: Does not stop disease progression. Effectiveness decreases over time. Side effects include nausea, diarrhea, loss of appetite, and sleep disturbances. Does not address underlying neurodegeneration.

2. NMDA Receptor Antagonist (memantine): • Mechanism: Blocks excessive glutamate activity, which can damage neurons. • Indication: Moderate to severe Alzheimer's. • Benefits: May slow cognitive decline slightly. Often used in combination with cholinesterase inhibitors. • Limitations: Symptom management only. Does not modify disease. Side effects include dizziness, confusion, and headache.

3. Anti-Amyloid Antibodies (lecanemab/Leqembi, donanemab): • Mechanism: Clear amyloid-beta plaques from the brain. • Indication: Early Alzheimer's (MCI or mild stage with confirmed amyloid pathology). • Benefits: Modest slowing of cognitive decline (approximately 27% reduction in decline rate over 18 months for lecanemab). • Limitations: Requires PET amyloid imaging or CSF analysis for eligibility. Intravenous infusions every 2-4 weeks. Risk of amyloid-related imaging abnormalities (ARIA) — brain swelling and microhemorrhages. Very expensive ($26,000-$30,000/year before monitoring costs). Does not reverse cognitive loss already sustained.

Cuba's NeuroEPO/NeuralCIM® Approach

Cuba's neuroprotective approach is fundamentally different from conventional drug therapy:

Mechanism: NeuroEPO is a recombinant human erythropoietin (EPO) formulation designed to cross the blood-brain barrier. Unlike conventional EPO (which primarily stimulates red blood cell production), NeuroEPO delivers neuroprotective effects directly to brain tissue:

• Neuroprotection — Protects neurons from oxidative stress, inflammation, and apoptosis (programmed cell death) • Anti-inflammatory — Reduces neuroinflammation, a key driver of Alzheimer's progression • Neuroplasticity support — Promotes the formation of new neural connections, supporting cognitive rehabilitation • Angiogenesis — Improves blood flow to brain tissue, supporting overall brain health • Multi-target action — Unlike single-pathway drugs, EPO's neuroprotective effects address multiple aspects of neurodegeneration simultaneously

The key distinction: conventional medications target a single pathway (acetylcholine, glutamate, or amyloid). NeuroEPO's neuroprotective properties address multiple pathological processes at once — oxidative stress, inflammation, apoptosis, and reduced neurotrophic support.

Integration with rehabilitation: NeuralCIM® is not administered as a standalone medication. It is part of Cuba's comprehensive multidisciplinary program that includes: • Intensive cognitive rehabilitation (4-6 hours daily) • Occupational therapy • Neuropsychological support • Physical therapy • Caregiver education

This integrated approach recognizes that neuroprotection alone is insufficient — the brain also needs active stimulation, structured rehabilitation, and functional support to maximize cognitive preservation.

Key Differences: Conventional vs. Cuba's Approach

Understanding the key differences helps patients make informed decisions:

Treatment Philosophy: • Conventional: Manage symptoms with daily oral medication, or slow amyloid accumulation with periodic infusions. • Cuba: Intensive, time-limited neuroprotective therapy combined with comprehensive cognitive rehabilitation — treating the whole patient, not just a molecular target.

Approach to Neurodegeneration: • Conventional: Targets single pathways (cholinesterase, NMDA receptors, or amyloid plaques). • Cuba: Multi-target neuroprotection addressing oxidative stress, inflammation, apoptosis, and neuroplasticity simultaneously.

Duration & Intensity: • Conventional: Ongoing daily medication, potentially for years. Minimal structured rehabilitation component. • Cuba: Intensive 4-6 week program in Havana combining neuroprotective therapy with daily cognitive rehabilitation, followed by telemedicine follow-up and home-based cognitive exercises.

Comprehensiveness: • Conventional: Primarily pharmacological — medication prescribed by neurologist. • Cuba: Multidisciplinary team — neurologist, neuropsychologist, occupational therapist, physical therapist, speech therapist, and caregiver educators working together.

Important Note: Cuba's approach is not a replacement for conventional treatment. Many international patients continue their conventional medications while undergoing Cuba's program. The decision to modify conventional treatment should be made in consultation with both the Cuban medical team and the patient's home-country neurologist. Cuba's program is complementary, not substitutive.